YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Pulmonx Corporation REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced that management will parti…
(RTTNews) - Today's top biotech gainers include Universe Pharmaceuticals, which recently filed its SEC report for the six months ended March 31, 2026; Cumberland Pharma, ahead of its second-quarter 2026 financial results due Tuesday; and A…
(RTTNews) - Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausc…
(RTTNews) - Pulmonx Corporation (LUNG), a medical device company focused on minimally invasive treatments for lung disease, yesterday announced financial results for the second quarter ended June 30, 2026, showing lower revenue compared to…
Key Points Interested in Pulmonx Corporation? Here are five stocks we like better. Pulmonx reported $22.8 million in Q2 revenue, down 5% year over year, but U.S. revenue rose 7% sequentially as the company rebuilt its sales force and added…
REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second qua…
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a firesid…
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on June 1, 2026 (the “Grant Da…
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.33 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.36 per share a year ago. These figures are adjusted for non-recurring items. A quarter ag…
Hims & Hers Health, Inc. HIMS shares soared 11.1% in the last trading session to close at $26.99. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 4.9% gain over…
Pulmonx logo Key Points Management says U.S. underperformance in 2025 was driven by “internal operational and executional challenges,” including disruptive territory changes and incentive design that contributed to turnover of about half o…
Image source: The Motley Fool. DATE Wednesday, March 4, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Glendon French Chief Operating Officer and Chief Financial Officer — Derrick Sung Need a quote from a Mo…
Image source: The Motley Fool. DATE Wednesday, March 4, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Glendon FrenchChief Operating Officer and Chief Financial Officer — Derrick Sung Need a quote from a Mot…
* Pulmonx press release [https://seekingalpha.com/pr/20424659-pulmonx-reports-fourth-quarter-and-full-year-2025-financial-results] (LUNG [https://seekingalpha.com/symbol/LUNG]): Q4 GAAP EPS of -$0.25 beats by $0.14. * Revenue of $22.59M (-…
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth qu…
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced the closing of a five-year credit…
Privia Health (PRVA) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items.…
Octopus AIM VCT 2 plc Portfolio Update The investment portfolio of Octopus AIM VCT 2 plc (the "Company") as at 9 January 2026 is as follows (the valuations being the unaudited valuations, at bid price, as at 30 November 2025): Investee Com…
REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on December 1, 2025 (the “Gran…
As the U.S. markets show resilience with major indexes rising despite mixed economic signals, investors are increasingly looking beyond traditional stocks to explore other opportunities. Penny stocks, often associated with smaller or newer…
Earnings Call Insights: Pulmonx Corporation (LUNG) Q3 2025 MANAGEMENT VIEW * CEO Glendon French announced his return to the CEO role and highlighted the reappointment of Derrick Sung as COO and CFO, citing Sung's "broad and diverse skill s…
As major U.S. stock indexes reach new highs, driven by solid corporate earnings and potential interest rate cuts, investors are increasingly looking beyond the giants of Wall Street for opportunities. Penny stocks—often representing smalle…
* Pulmonx press release [https://seekingalpha.com/pr/20280941-pulmonx-announces-management-transition-and-preliminary-third-quarter-2025-revenue] (NASDAQ:LUNG [https://seekingalpha.com/symbol/LUNG]): Q3 revenue expected to be approximately…
(RTTNews) - Several healthcare and biotech stocks posted notable gains in after-hours trading on Monday, driven by earnings updates, executive appointments, and capital market activity. Pulmonx Corp. (LUNG) surged 33.33% to $2.08 as of 9:3…
Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive OfficerDerrick Sung, former Pulmonx Chief Financial Officer, appointed Chief Operating Office…
REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial resu…
REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that management will present at the…
Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Healthcare, Consumer Goods and Financials sectors led shares lower. At the close in NYSE, the Dow Jones Industrial Average declined 0.74%, while the S&P 5…
[USA Recession and Crashing Economy Concept] mphillips007 Pulmonx (NASDAQ:LUNG [https://seekingalpha.com/symbol/LUNG]) shares plunged ~41% on Thursday after the lung device maker, with its second-quarter financials, lowered its full-year r…
Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] GAINERS TICKER CHANGE COMMENT SNGX [https://www.char…
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. [topmovers] GAINERS TICKER CHANGE COMMENT VRME [https://www.chartmill.com/stock/quote/VRME/profile] 92.03% Exciting news for…
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. [gap] GAP UP STOCKS TICKER CHANGE COMMENT SNGX [https://www.chartm…
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT VRME [h…
Investing.com - Piper Sandler downgraded Pulmonx Corp . (NASDAQ:LUNG) from Overweight to Neutral on Thursday, while significantly reducing its price target to $2.50 from $9.00 following the company’s second-quarter report. The stock, which…
Earnings Call Insights: Pulmonx Corporation (LUNG) Q2 2025 MANAGEMENT VIEW * Steven S. Williamson, CEO, highlighted second quarter 2025 revenue of $23.9 million and emphasized international performance, stating, "Our international business…
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.39 per share a year ago. These figures are adjusted for non-recurring items.…